De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Ningbo Menovo Pharmaceutical Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Ningbo Menovo Pharmaceutical's earnings have been declining at an average annual rate of -7.3%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 1.7% per year.
Belangrijke informatie
-7.3%
Groei van de winst
-8.7%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 10.9% |
| Inkomstengroei | 1.7% |
| Rendement op eigen vermogen | 0.1% |
| Nettomarge | -0.03% |
| Volgende winstupdate | 30 Oct 2024 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe Ningbo Menovo Pharmaceutical geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 1,242 | 0 | 222 | 102 |
| 31 Mar 24 | 1,233 | -18 | 223 | 100 |
| 31 Dec 23 | 1,216 | 12 | 220 | 95 |
| 30 Sep 23 | 1,155 | 179 | 242 | 91 |
| 30 Jun 23 | 1,142 | 185 | 239 | 90 |
| 31 Mar 23 | 1,203 | 267 | 237 | 101 |
| 31 Dec 22 | 1,457 | 339 | 248 | 98 |
| 30 Sep 22 | 1,570 | 221 | 235 | 109 |
| 30 Jun 22 | 1,464 | 211 | 217 | 106 |
| 31 Mar 22 | 1,420 | 207 | 209 | 84 |
| 31 Dec 21 | 1,258 | 143 | 196 | 88 |
| 30 Sep 21 | 1,163 | 150 | 170 | 88 |
| 30 Jun 21 | 1,234 | 166 | 170 | 78 |
| 31 Mar 21 | 1,246 | 163 | 178 | 79 |
| 31 Dec 20 | 1,193 | 156 | 169 | 74 |
| 30 Sep 20 | 1,278 | 164 | 210 | 56 |
| 30 Jun 20 | 1,270 | 171 | 209 | 55 |
| 31 Mar 20 | 1,211 | 152 | 191 | 52 |
| 31 Dec 19 | 1,180 | 151 | 186 | 53 |
| 30 Sep 19 | 1,142 | 160 | 157 | 50 |
| 30 Jun 19 | 1,062 | 138 | 146 | 45 |
| 31 Mar 19 | 949 | 131 | 144 | 40 |
| 31 Dec 18 | 849 | 96 | 131 | 39 |
| 30 Sep 18 | 735 | 73 | 110 | 33 |
| 30 Jun 18 | 650 | 57 | 88 | 46 |
| 31 Mar 18 | 615 | 39 | 87 | 40 |
| 31 Dec 17 | 605 | 45 | 97 | 32 |
| 30 Sep 17 | 560 | 53 | 95 | 20 |
| 30 Jun 17 | 584 | 71 | 111 | 0 |
| 31 Mar 17 | 595 | 80 | 107 | 0 |
| 31 Dec 16 | 578 | 79 | 106 | 0 |
| 31 Dec 15 | 597 | 77 | 106 | 0 |
| 31 Dec 14 | 636 | 73 | 102 | 0 |
| 31 Dec 13 | 502 | 69 | 79 | 0 |
Kwaliteitswinsten: 603538 is currently unprofitable.
Groeiende winstmarge: 603538 is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 603538 is unprofitable, and losses have increased over the past 5 years at a rate of 7.3% per year.
Versnelling van de groei: Unable to compare 603538's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: 603538 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.6%).
Rendement op eigen vermogen
Hoge ROE: 603538 has a negative Return on Equity (0.13%), as it is currently unprofitable.